Abstract:CD133, a cancer stem cell (CSC) marker in tumors, including melanoma, is associated with tumor recurrence, chemoresistance, and metastasis. Patient-derived melanoma cell lines were transduced with a Tet-on vector expressing CD133, generating doxycycline (Dox)-inducible cell lines. Cells were exposed to Dox for 24 h to induce CD133 expression, followed by RNA-seq and bioinformatic analyses, revealing genes and pathways that are significantly up- or downregulated by CD133. The most significantly upregulated gene after CD133 was amphiregulin (AREG), validated by qRT-PCR and immunoblot analyses. Induced CD133 expression significantly increased cell growth, percentage of cells in S-phase, BrdU incorporation into nascent DNA, and PCNA levels, indicating that CD133 stimulates cell proliferation. CD133 induction also activated EGFR and the MAPK pathway. Potential mechanisms highlighting the role(s) of CD133 and AREG in melanoma CSC were further delineated using AREG/EGFR inhibitors or siRNA knockdown of AREG mRNA. Treatment with the EGFR inhibitor gefitinib blocked CD133-induced cell growth increase and MAPK pathway activation. Importantly, siRNA knockdown of AREG reversed the stimulatory effects of CD133 on cell growth, indicating that AREG mediates the effects of CD133 on cell proliferation, thus serving as an attractive target for novel combinatorial therapeutics in melanoma and cancers with overexpression of both CD133 and AREG.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: How does CD133 promote the proliferation of melanoma cells by up - regulating Amphiregulin (AREG)? Specifically, the study aims to explore the mechanism of action of CD133 in melanoma, especially how it affects cell proliferation, cell - cycle progression, and the activation of related signaling pathways (such as the EGFR and MAPK pathways). In addition, the study also evaluates the possibility of AREG as a therapeutic target to develop new combination therapies for melanoma and other cancers with over - expressed CD133 and AREG. ### Research Background Malignant melanoma (MM) is one of the most deadly types of skin cancer, and its incidence continues to rise globally. Although there have been improvements in disease management in recent years, the mortality rate among patients remains high, especially in NRAS - mutant melanomas, where resistance to existing therapies and tumor recurrence are particularly prominent problems. Therefore, it is crucial to find new treatment strategies. ### The Role of CD133 CD133 is a marker associated with cancer stem cells (CSC) and has been found in various tumors, including melanoma. It is related to tumor recurrence, chemotherapy resistance, and metastasis. In this study, by inducing CD133 expression, its effects on cell proliferation and signaling pathways were revealed, and AREG was found to be a significantly up - regulated gene. ### The Role of AREG AREG is a 43 - kDa transmembrane glycoprotein ligand that can bind to the epidermal growth factor receptor (EGFR) and strongly activate the MAPK RAS - RAF - MEK/ERK and PI3K/AKT signaling pathways, which are closely related to cell proliferation, migration, and survival. The study further verified the crucial role of AREG in CD133 - induced cell proliferation and growth, and tested the feasibility of targeting AREG by siRNA and small - molecule or antibody inhibitors. ### Main Conclusions 1. **CD133 Up - regulates AREG**: After Dox - induced CD133 expression, the expression level of AREG increased significantly. 2. **Promote Cell Proliferation**: The expression of CD133 significantly increased cell growth, the proportion of S - phase cells, BrdU incorporation into newly synthesized DNA, and PCNA levels. 3. **Activate EGFR and MAPK Pathways**: CD133 induction also activated the EGFR and MAPK pathways. 4. **AREG Mediates CD133 Effects**: Knocking down AREG mRNA by siRNA or using the EGFR inhibitor gefitinib can block the CD133 - induced increase in cell growth and MAPK pathway activation, indicating that AREG plays a crucial role in CD133 - mediated cell proliferation. In conclusion, this study reveals the specific mechanism by which CD133 promotes the proliferation of melanoma cells by up - regulating AREG, and provides a theoretical basis for the development of new therapies targeting CD133 and AREG.

CD133 Stimulates Cell Proliferation via the Upregulation of Amphiregulin in Melanoma

CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance

Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells.

Quantitative Analyses of CD133 Expression Facilitate Researches on Tumor Stem Cells.

New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation

CD133 Antigen as a Potential Marker of Melanoma Stem Cells: In Vitro and In Vivo Studies

Activation of Akt and MAPK Pathways Enhances the Tumorigenicity of CD133+ Primary Colon Cancer Cells

Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells

G Protein-Coupled Receptor 87 (Gpr87) Promotes The Growth And Metastasis Of Cd133(+) Cancer Stem-Like Cells In Hepatocellular Carcinoma

CD147-targeted Sirna in A375 Malignant Melanoma Cells Induces the Phosphorylation of EGFR and Downregulates Cdc25c and MEK Phosphorylation.

MicroRNA-92 Expression in CD133+ Melanoma Stem Cells Regulates Immunosuppression in the Tumor Microenvironment via Integrin-Dependent Activation of TGFβ

CD133: a cancer stem cells marker, is used in colorectal cancers.

Role of CD133/NRF2 Axis in the Development of Colon Cancer Stem Cell-Like Properties

ABCG2 is Required for Self-Renewal and Chemoresistance of CD133-positive Human Colorectal Cancer Cells

CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer

Epigenetic Regulation Of Cd271, A Potential Cancer Stem Cell Marker Associated With Chemoresistance And Metastatic Capacity

Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody.

Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells

The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.

Expression of CD133 in endometrial cancer cells and its implications

Cancer Stem Cell Marker CD133+ Tumour Cells and Clinical Outcome in Rectal Cancer